{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:03:15Z","timestamp":1787749395698,"version":"build-2784847793"},"reference-count":33,"publisher":"Royal College of General Practitioners","issue":"745","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Gen Pract"],"accepted":{"date-parts":[[2024,3,27]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Screening is not recommended for prostate cancer in the UK. Asymptomatic men aged \u226550 years can request a prostate-specific antigen (PSA) test following counselling on potential harms and benefits. There are areas of clinical uncertainty among GPs, resulting in the content and quality of counselling varying.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim<\/jats:title>\n<jats:p>To produce a consensus that can influence guidelines for UK primary care on the optimal use of the PSA test in asymptomatic men for early prostate cancer detection.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design and setting<\/jats:title>\n<jats:p>Prostate Cancer UK facilitated a RAND\/UCLA consensus.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method<\/jats:title>\n<jats:p>Statements covering five topics were developed with a subgroup of experts. A panel of 15 experts in prostate cancer scored (round one) statements on a scale of one (strongly disagree) to nine (strongly agree). Panellists met to discuss statements before rescoring (round two). A lived experience panel of seven men scored a subset of statements with outcomes fed into the main panel.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of the initial 94 statements reviewed by the expert panel, a final 48\/85 (56%) achieved consensus. In the absence of screening, there was consensus on proactive approaches to initiate discussions about the PSA test with men who were at higher-than-average risk.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Improvements in the prostate cancer diagnostic pathway may have reduced some of the harms associated with PSA testing; however, several areas of uncertainty remain in relation to screening, including optimal PSA thresholds for referral and intervals for retesting. There is consensus on proactive approaches to testing in higher-than-average risk groups. This should prompt a review of current guidelines.<\/jats:p>\n<\/jats:sec>","DOI":"10.3399\/bjgp.2023.0586","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:25:37Z","timestamp":1721694337000},"page":"e534-e543","source":"Crossref","is-referenced-by-count":14,"title":["Optimising the use of the prostate-\u200aspecific antigen blood test in asymptomatic men for early prostate cancer detection in primary care: report from a UK clinical consensus"],"prefix":"10.3399","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0973-0302","authenticated-orcid":false,"given":"Thomas A","family":"Harding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7992-7719","authenticated-orcid":false,"given":"Richard M","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2919-9087","authenticated-orcid":false,"given":"Samuel WD","family":"Merriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2904-6980","authenticated-orcid":false,"given":"Robert","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6999-2739","authenticated-orcid":false,"given":"Joe M","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-7714","authenticated-orcid":false,"given":"Mike","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwabunmi","family":"Olajide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4889-5154","authenticated-orcid":false,"given":"Jaimin","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9547-9353","authenticated-orcid":false,"given":"Oliver","family":"Hulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5226-4073","authenticated-orcid":false,"given":"Tanimola","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4722-4207","authenticated-orcid":false,"given":"Vincent J","family":"Gnanapragasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-4720","authenticated-orcid":false,"given":"Jonathan","family":"Aning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9086-3592","authenticated-orcid":false,"given":"Derek J","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0843-2468","authenticated-orcid":false,"given":"Nora","family":"Pashayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2209-5808","authenticated-orcid":false,"given":"Abel","family":"Tesfai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6611-118X","authenticated-orcid":false,"given":"Natalia","family":"Norori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rylance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2611-5788","authenticated-orcid":false,"given":"Andrew","family":"Seggie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"2024120415350976000_74.745.e534.1","unstructured":"Cancer Research UK Prostate cancer statistics: prostate cancer mortality. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer (accessed 9 Jul 2024)."},{"key":"2024120415350976000_74.745.e534.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-9083-8"},{"issue":"17","key":"2024120415350976000_74.745.e534.3","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"key":"2024120415350976000_74.745.e534.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"2024120415350976000_74.745.e534.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"key":"2024120415350976000_74.745.e534.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.09.034"},{"key":"2024120415350976000_74.745.e534.7","unstructured":"UK National Screening Committee (2020) Adult screening programme: prostate cancer. https:\/\/view-health-screening-recommendations.service.gov.uk\/prostate-cancer (accessed 9 Jul 2024)."},{"key":"2024120415350976000_74.745.e534.8","unstructured":"Office for Health Improvement and Disparities (2022) Prostate specific antigen testing: summary guidance for GPs. https:\/\/www.gov.uk\/government\/publications\/prostate-specific-antigen-testing-explanation-and-implementation (accessed 9 Jul 2024)."},{"key":"2024120415350976000_74.745.e534.9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-8-35"},{"key":"2024120415350976000_74.745.e534.10","unstructured":"Fitch K Bernstein SJ Aguilar MD (2001) The RAND\/UCLA appropriateness method user\u2019s manual, https:\/\/www.rand.org\/content\/dam\/rand\/pubs\/monograph_reports\/2011\/MR1269.pdf (accessed 9 Jul 2024)."},{"key":"2024120415350976000_74.745.e534.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1"},{"issue":"11","key":"2024120415350976000_74.745.e534.12","doi-asserted-by":"crossref","first-page":"894.e11","DOI":"10.1016\/j.crad.2019.09.129","article-title":"Prostate mpMRI in the UK: the state of the nation","volume":"74","author":"Davies","year":"2019","journal-title":"Clin Radiol"},{"issue":"19","key":"2024120415350976000_74.745.e534.13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2024120415350976000_74.745.e534.14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/bco2.321","article-title":"The impact of pre-biopsy MRI and additional testing on prostate cancer screening outcomes: a rapid review","volume":"5","author":"Tesfai","year":"2024","journal-title":"BJUI Compass"},{"key":"2024120415350976000_74.745.e534.15","unstructured":"National Prostate Cancer Audit (2021) Using the Cambridge Prognostic Groups for risk stratification of prostate cancer in the National Prostate Cancer Audit: how could it impact our estimates of potential \u2018over-treatment\u2019? https:\/\/www.npca.org.uk\/reports\/npca-short-report-2021 (accessed 9 Jul 2024)."},{"key":"2024120415350976000_74.745.e534.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.07.024"},{"key":"2024120415350976000_74.745.e534.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.06.026"},{"issue":"3","key":"2024120415350976000_74.745.e534.18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eururo.2020.04.016","article-title":"Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence","volume":"78","author":"Vickers","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"2024120415350976000_74.745.e534.19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41391-021-00478-2","article-title":"Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study","volume":"25","author":"Kornienko","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"2024120415350976000_74.745.e534.20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/bco2.326","article-title":"Variation in harms and benefits of prostate-specific antigen screening for prostate cancer by socio-clinical risk factors: a rapid review","volume":"5","author":"Tesfai","year":"2024","journal-title":"BJUI Compass"},{"key":"2024120415350976000_74.745.e534.21","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2205"},{"key":"2024120415350976000_74.745.e534.22","doi-asserted-by":"publisher","DOI":"10.1177\/20514158221091402"},{"key":"2024120415350976000_74.745.e534.23","doi-asserted-by":"crossref","unstructured":"Kirby M Merriel SWD Olajide O (2024) Is the digital rectal exam any good as a prostate cancer screening test? Br J Gen Pract, DOI: https:\/\/doi.org\/10.3399\/bjgp24X736677.","DOI":"10.3399\/bjgp24X736677"},{"key":"2024120415350976000_74.745.e534.24","unstructured":"National Institute for Health and Care Excellence (NICE) (2021) Prostate cancer: diagnosis and management. NG131 (NICE, London) https:\/\/www.nice.org.uk\/guidance\/ng131\/chapter\/Recommendations (accessed 9 Jul 2024)."},{"key":"2024120415350976000_74.745.e534.25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12916-015-0405-5","article-title":"Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008\u20132010","volume":"13","author":"Lloyd","year":"2015","journal-title":"BMC Med"},{"key":"2024120415350976000_74.745.e534.26","unstructured":"European Commission (2022) Proposal for a Council recommendation on strengthening prevention through early detection: a new EU approach on cancer screening replacing Council Recommendation 2003\/878\/EC, https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A52022DC0474 (accessed 9 Jul 2024)."},{"key":"2024120415350976000_74.745.e534.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.264"},{"issue":"2","key":"2024120415350976000_74.745.e534.28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41391-022-00613-7","article-title":"Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review","volume":"26","author":"Barlow","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2024120415350976000_74.745.e534.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000057"},{"key":"2024120415350976000_74.745.e534.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017729"},{"issue":"12","key":"2024120415350976000_74.745.e534.31","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1001\/jamaoncol.2022.4319","article-title":"Association of prostate-specific antigen screening rates with subsequent metastatic prostate cancer incidence at US Veterans Health","volume":"8","author":"Bryant","year":"2022","journal-title":"JAMA Oncol"},{"key":"2024120415350976000_74.745.e534.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p284"},{"key":"2024120415350976000_74.745.e534.33","unstructured":"NHS England (2023) Network Contract Directed Enhanced Service: early cancer diagnosis support pack, https:\/\/www.england.nhs.uk\/publication\/network-contract-des-early-cancer-diagnosis-guidance-for-2023-24 (accessed 9 Jul 2024)."}],"container-title":["British Journal of General Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGP.2023.0586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T04:16:13Z","timestamp":1733372173000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgp.org\/lookup\/doi\/10.3399\/BJGP.2023.0586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":33,"journal-issue":{"issue":"745","published-online":{"date-parts":[[2024,7,25]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.3399\/BJGP.2023.0586"],"URL":"https:\/\/doi.org\/10.3399\/bjgp.2023.0586","relation":{},"ISSN":["0960-1643","1478-5242"],"issn-type":[{"value":"0960-1643","type":"print"},{"value":"1478-5242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}